Serum Mannan-Binding Lectin in Egyptian Patients With Chronic Hepatitis C: Its Relation to Disease Progression and Response to Treatment

Serag Esmat 1*, Dalia Omran 2, Gihan A. Sleem 1, Laila Rashed 3
1 Department of Internal Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt
2 Department of Tropical Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt
3 Department of Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt

ARTICLE INFO

Article type: Original Article

Article history:
Received: 13 Apr 2011
Revised: 30 Apr 2011
Accepted: 10 May 2011

Keywords:
Hepatitis C
Interferon
Mannan
Egypt

ABSTRACT

Background: Chronic hepatitis C virus (HCV) infection is a major worldwide public health problem. Egypt has the highest prevalence of adult HCV infection in the world, averaging 15%–25% in rural communities. Mannan-binding lectin (MBL) is a liver-derived pluripotent serum lectin that plays a role in the innate immune system of the host. It is an acute-phase protein that is involved in the activation of the classical complement pathway. MBL may play a defensive role in HCV infection.

Objectives: To investigate the relationship between MBL concentration and HCV infection in Egyptian patients suffering chronic hepatitis C.

Patients and Methods: Serum samples obtained from 35 Egyptian hepatitis C patients and 30 normal controls were assayed for MBL. MBL concentrations were correlated to disease characteristics and treatment response.

Results: Serum MBL was significantly higher in HCV patients than in controls, but no relationship was found between MBL concentration and disease progression in terms of hepatic fibrosis and inflammation. Responders to interferon (INF)-based therapy had significantly higher serum MBL than non-responders.

Conclusions: We found no association between serum MBL concentration and progression of HCV related liver disease. Responders to INF-based therapy had significantly higher serum MBL than non-responders.

Implication for health policy/practice/research/medical education: MBL may be considered as a predictor of response to antiviral therapy in HCV patients and MBL replacement therapy may improve the response to antiviral therapy in these patients.

Please cite this paper as:
Esmat S, Omran D, Sleem GA, Rashed L. Serum Mannan-Binding Lectin in Egyptian Patients With Chronic Hepatitis C: Its Relation to Disease Progression and Response to Treatment. Hepat Mon. 2012;12(4):259-64. DOI: 10.5812/hepatmon.704

1. Background

Mannan-binding lectin (MBL) is an acute-phase protein that is involved in the activation of the classical complement pathway (1). MBL acts as a direct opsonin by binding to collectin receptors through its collagen domain (2). Serum levels of MBL in humans are highly influenced by inherited haplotypes that differ at a series of allelic polymorphisms. These differences can influence the structural gene and its promoter region (3-5). Other factors can affect plasma MBL, including growth hormone (6). The MBL genotype of a person provides only a general idea of the expected plasma concentration and different combinations of haplotypes are associated with a wide range of MBL concentrations (4, 5). Genotypes are good indicators...
of the average MBL concentrations of populations; however, they provide a less reliable prediction of plasma MBL for individuals (4). Approximately 60–85% of those infected with HCV cannot eradicate the virus and progress to chronic hepatitis (7, 8). This high rate of viral chronicity may be explained by a failure in the host immune response or by the ability of HCV to defeat host defense mechanisms (7, 8). MBL acts as a recognition molecule for pathogen-associated molecular patterns (PAMPs) which play a role in the initiation and regulation of the immune response (9). The role of MBL in HCV pathogenesis has received a lot of attention in the last few years (10). MBL activates the complement system, which results in destruction of pathogens by the membrane attack complex or by complement-mediated phagocytosis. MBL can engage in phagocytosis of infection agents to modulate the release of proinflammatory cytokines (10-12). Many previous studies of MBL and hepatitis C based diagnoses solely on serology, but included patients with different clinical forms of HCV infection ranging from those with no liver involvement, to those with cirrhosis. This compromises the analyses of the severity of liver involvement (13-17). Studying the results of liver biopsies is the gold standard for grading hepatitis C. MBL may play an immunomodulatory role during treatment with IFN, as MBL regulates the release of different cytokines from immune cells in response to infection (18).

Hepatitis C-infected patients with MBL haplotypes that were known to confer low MBL concentrations are significantly less likely to respond to interferon (INF) therapy than similar patients who are genetically able to produce greater amounts of MBL (14). This may be important, because the expense, adverse side-effects, and long duration of antiviral therapy make screening for potential non-responders desirable (14). The clear implication that MBL plays a major role in elimination of the virus raises the possibility that MBL replacement therapy may be beneficial for hepatitis C carriers with low levels of MBL (14). However, at least one other study (19) found that susceptibility to hepatitis C infection is not increased by low circulating MBL, and MBL concentration does not play a big role in the course of the disease or patient response to antiviral therapy. If this is the case, MBL replacement therapy would not be beneficial for chronic hepatitis C patients who failed to respond fully to treatment with interferon and ribavirin (19).

2. Objectives

We therefore aimed to investigate the relationship between MBL concentration and hepatitis C infection at the protein level in Egyptian patients suffering from chronic hepatitis C.

3. Patients and Methods

3.1. Patients

Thirty-five randomly selected HCV patients that were candidates for IFN-based therapy and 30 healthy volunteers participated in the study. Patients were recruited from the outpatient clinics of the internal medicine and tropical medicine departments, Kasr Al Aini hospital, Cairo University.

3.2. Methods

We collected serum samples from all patients and controls. Serum was tested for HCV antibodies and MBL concentration. Other laboratory tests included fasting blood glucose, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, serum creatinine, serum albumin and complete blood count. Samples were drawn after an overnight fast and were measured using standard commercial methods on a parallel multi-channel analyzer (Hitachi 7170A, Tokyo, Japan). All HCV patients were subjected to the following: 1) quantitative polymerase chain reaction (PCR) assay for HCV before starting treatment and 12 weeks after beginning treatment. Patients that responded to treatment were tested again 6 months after beginning and at the end of treatment. 2) Liver biopsy as a routine measure before starting treatment. 3) Alpha-fetoprotein (AFP). PCR for HCV RNA was performed on samples from controls as well as patients. All participants in the control group tested negative.

HCV RNA was extracted from a 200 μL serum sample using Ana-gen RNA extraction kit (Qiagen, USA) according to the manufacturer’s instructions. cDNA was prepared by Reverse transcription PCR using M-MLV reverse transcriptase (Fermentas, USA). The amplified cDNA was further subjected to 2 rounds of PCR amplifications using a highly conserved primer sequence, upstream primer 5′-GCAGAAAGCGTCTAGCCATGGCGT and downstream primer, 5′-CTCGCAAGCACCCTATCAGGGAGT. The conditions for the first round of PCR were as follows: an initial denaturation step at 95°C for 2 min followed by 30 cycles of 45 s at 94°C, 45 s at 54°C, and 1 min at 72°C. PCR cycling conditions for the second round are as for first round amplification except for an annealing temperature of 54°C. All PCR products (first and second rounds) were analyzed on 1.8% agarose gel prepared in 0.5% TBE buffer, stained with ethidium bromide and visualized by ultraviolet (20). Ultrasound-guided biopsy was performed for all patients using 18-20 gauge needles, (GHATWARY MEDICAL SUPPLIES, Alexandria, Egypt). Diagnostic liver biopsy specimens were scored using the Ishak modified histological activity index (HAI) and Ishak fibrosis stages (21). Before treatment, MBL was measured in serum samples using an enzyme-linked immunosorbetant assay (ELISA) kit (Hycult Biotech, Uden, Netherlands). Briefly, a standard curve was prepared by serial dilution of standards supplied with the assay. Standards and serum samples were added to a 96-well plate containing immobilized antibodies specific to MBL. The plate was incubated at room temperature for 2 h, with gentle shaking. Following extensive washing, bound MBL was detected using
an HRP-conjugated polyclonal antibody against the target protein. The detection antibody was incubated for 2 h at room temperature, and detected using 3,3′,5′-tetramethylbenzidine (TMB) and 3% H$_2$O$_2$. The reaction was terminated by the addition of sulfuric acid provided with the kit. Optical density was detected using a microplate reader at 450 nm with a wavelength correction reading at 540 nm. Concentrations of unknowns were calculated from the standard curve (22).

Patients were given a course of antiviral therapy consisting of Peginterferon alfa-2a (Pegasys®) 180 mcg (regardless of body weight) subcutaneously once weekly and 10.6 mg/kg ribavirin orally every day (combination therapy). Informed consent was obtained from all patients and controls. Based therapy was continued for a total of 48 weeks. Responders (n = 20) were tested again 6 months after the end of therapy using PCR to ensure sustained virological response (SVR). Patients with PCR scores that were not at least 2 logs lower after 12 weeks of therapy than at baseline were deemed to be non-responders (n = 11). Four patients were lost to follow-up during INF-based therapy. Informed consent was obtained from all patients and controls.

3.3. Statistical Analysis

All patient data were tabulated using Excel 7. Data were then processed using SPSS (Statistical Package for Science and Society) version 17.0 (SPSS Inc., Chicago, IL, USA) for Windows 7 (Microsoft, Corporation, NY, USA). Descriptive statistics are presented as means ± standard deviations (SD) for quantitative variables. All qualitative data are expressed as frequencies (number) and percentages. Groups were compared using chi-square test and Fisher’s test, as appropriate for qualitative data. Independent sample t-test was used for comparing normally distributed quantitative variables between groups and non-parametric Mann–Whitney test and Kruskal–Wallis test were used to compare abnormally distributed quantitative variables between groups. Correlation analysis was used when appropriate. P values lower than 0.05 were considered statistically significant for all tests.

4. Results

Our study included 35 patients between 19 and 56 years of age (20 males, 15 females, mean age: 37.43 ± 9.65). Baseline characteristics of patients are summarized in Table 1. The control group included 30 healthy subjects between 18 and 55 years of age (18 males, 12 females, mean age: 36.8 ± 11.885). The characteristics of the control group are shown in Table 1. We performed multivariate analysis to adjust for age and gender effects, but neither age nor gender significantly affected other variables (P > 0.05). MBL concentrations were significantly higher in chronic hepatitis C patients (P < 0.001) than in controls (1330.47 ± 497.81 ng/mL in patients vs. 619 ± 136 ng/mL in the controls; Figure 1). There was a significant positive correlation between serum MBL level and alpha-fetoprotein in the HCV infected group (Figure 2). Within the HCV group, the fibrosis scores were 1, 2, and 3 in 10, 7, and 18 patients, respectively. The activity score for inflammation was 1, 2, and 3 in 10, 7, and 18 patients, respectively (Table 2). MBL concentrations did not differ significantly between different grades of liver fibrosis and liver inflamma-

### Table 1. Baseline Characteristics of HCV Patients and Healthy Controls

|              | Patients               | Control Group          |
|--------------|------------------------|------------------------|
| Age, y       | Minimum 19, Maximum 56 | Minimum 18, Maximum 55 |
| Body weight, Kg | 53, 105               | 66, 107                |
| Blood glucose, mg/dL | 60, 321           | 68, 112               |
| Creatinine, mg/dL | 0.44, 1.30           | 0.4, 1.1              |
| ALP a, IU/L  | 6.20, 252.00          | 56, 129               |
| AST a, IU/L  | 10, 283               | 13, 30                |
| ALT a, IU/L  | 8, 243                | 12, 30                |
| T. Bilirubin a, mg/dL | 0.24, 1.80          | 0.22, 1               |
| Albumin, gm/dL | 3.2, 5.10            | 3.9, 4.9              |
| Hb a, gm/dL  | 11.0, 16.9            | 10.9, 14.8            |
| Platelet/cm³ | 110,000, 3470000     | 222,000, 3900000      |
| WBCs a/cm³  | 3100, 11720           | 4200, 9000            |
| AFP a, ng/mL | 1.6, 44.1             | --                    |
| MBL a, ng/mL | 146.3, 2163.0         | 502, 916              |

*Abbreviations: AFP, alpha-fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Hb, hemoglobin; MBL, mannan binding lectin; T Bilirubin, total bilirubin; WBC, white blood cell.*
Table 2. Serum MBL in Different Grades of Liver Fibrosis and Hepatic Inflammation in the Patients Infected With HCV

| Frequency, No. | MBL a, ng/mL, mean ± SD | P value |
|---------------|--------------------------|--------|
| Fibrosis score |                          |        |
| 1             | 1285.46 ± 438.42         | 0.79 b |
| 2             | 1317.02 ± 540.5          |        |
| 3             | 1447.9 ± 513.6           |        |
| Activity score|                          |        |
| 1             | 1259.82 ± 622.11         | 0.52   |
| 2             | 1337.5 ± 458.5           |        |
| 3             | 1471.3 ± 480.8           |        |

a Abbreviation: MBL, Mannan Binding Lectin
b Kruskal-Wallis test was performed to obtain the P value

Table 3. Serum MBL Among Responders and Non-Responders to INF-Based Therapy a

| Patient Groups (n = 35) | No. | MBL, ng/mL |
|------------------------|-----|------------|
| Non responders b       | 11  | 1023.78 ± 163.11 |
| Responders c           | 20  | 1882.36 ± 291.34 |
| Missed d               | 4   | 1879.87 ± 217.25 |

a P < 0.001; Kruskal-Wallis test was performed to obtain the P value
b Less than 2 logs reduction in PCR after 12 weeks of therapy
c More than 2 logs reduction in PCR after 12 weeks of therapy and negative PCR at week 72 (SVR)
d More than 2 logs reduction in the PCR after 12 weeks of therapy, but dropped out of study before completion of the 48-week course of therapy

Figure 1. Mean Serum MBL Concentration Was Significantly Higher in Chronic Hepatitis C Patients Than in Controls (P < 0.001; Mann-Whitney Test).

5. Discussion

Egypt has the highest prevalence of adult HCV infection in the world, as 15%-25% of the population in rural communities is infected (23, 24). The outcome of HCV infections are usually associated with the interaction between the virus and the host immune response (25). Mannan-binding lectin (MBL) is a liver-derived pluripotent serum lectin that plays a role in the host immune system (12). The current study investigated the serum MBL level among Egyptian patients with chronic hepatitis C. We found that chronic HCV patients had higher MBL concentrations than healthy controls. This can be explained by the fact that MBL is an acute phase reactant (26). However, our results contradict those of Yuen M-F et al. 1999 (27) who reported that asymptomatic HCV patients had lower MBL levels than controls. While not statistically significant, MBL concentration tended to increase with the grades of fibrosis and hepatic inflammation. Other authors have also observed a statistically non-significant link between high serum MBL and more severe fibrosis (28). Further studies with larger numbers of patients are needed to assess this relationship. Although the association between the concentration of MBL and hepatitis severity was not statistically significant, it may still be real, and may reflect MBL’s role as an acute phase reactant. This is consistent with the highly significant increase in MBL in hepatitis C patients as compared to normal controls that we observed.

Serial AFP measurements in patients with chronic
Serum Mannan-Binding Lectin and Chronic Hepatitis C

Esmat S et al.

hepatitis C are useful for identifying persons with advanced fibrosis and help to determine which patients need periodic liver ultrasound screening to detect HCC (29). In our study, a significant positive correlation was found between serum MBL and AFP level. Moreover, both increased as the fibrosis stage became more advanced. This finding supports the hypothesis that MBL may be related to disease progression. In the current study, non-responders to INF-based therapy had significantly lower serum MBL than responders. However, both had significantly higher MBL levels than normal controls. The lower levels of MBL in non-responders may be explained by the inhibitory effect of HCV on MBL production from the liver (13). Those with higher levels of MBL may have a better ability to eliminate the virus (14). MBL may play an immunomodulatory role during treatment with IFN, as MBL regulates the release of various cytokines from immune cells in response to infection (18).

Progression of chronic hepatitis B and C are reported to be associated with MBL insufficiency (13-15, 30). Thio et al. (31) reported that recovery from hepatitis B infection was associated with high MBL serum levels while persistence of the virus was associated with low MBL serum levels. Liver cirrhosis has also been linked to low serum levels of MBL (27). Additionally, spontaneous bacterial peritonitis (SBP) is much more common in MBL-deficient cirrhotics (27). SBP is a serious disease and prevention of SBP in MBL-deficient cirrhotics with MBL therapy would be a valuable advance. This disease is a good candidate for a clinical trial of MBL therapy. Responders to INF-based therapy had significantly higher serum MBL than non-responders. MBL may be a predictor of antiviral therapy response in HCV patients. Further studies are needed to evaluate MBL replacement therapy, which may improve the response to antiviral therapy in these patients. The possible relationship between serum MBL concentration and progression of HCV-related liver disease deserves further evaluation with a larger number of patients.

Acknowledgments
None declared.

Authors’ Contribution
None declared.

Financial Disclosure
None declared.

Funding/Support
None declared.

References
1. Matsuhashi M, Fujita T. Activation of the classical complement pathway by mannan-binding protein in association with a novel C1s-like serine protease. J Exp Med. 1992;176(6):1497-502.
2. Ikeda K, Sannoh T, Kawasaki N, Kawasaki T, Yamashina I. Serum lectin with known structure activates complement through the classical pathway. J Biol Chem. 1987;262(16):7451-4.
3. Kilpatrick DC. Handbook of animal lectins: properties and biomedical applications. Wiley; 2000.
4. Kilpatrick DC. Mannan-binding lectin: clinical significance and applications. Biochim Biophys Acta. 2006;1762(3-4):409-13.
5. Steffensen R, Thiel S, Varming K, Jersild C, Jensens U. Clinical manifestations of mannan-binding lectin deficiency. J Mol Immunol. 2000;245(1-2):233-42.
6. Hansen TK, Thiel S, Dall R, Rosenfalck AM, Trainer P, Flyvbjerg A, et al. GH strongly affects serum concentrations of mannan-binding lectin: evidence for a new IGF-independent immunomodulatory effect of GH. J Clin Endocrinol Metab. 2001;86(6):2417-21.
7. Graikou A, Hepatitis C virus infection. How does the host respond? Minerva Gastroenterol Dietol. 2004;50(1):218.
8. Greimion C, Cerny A. Hepatitis C virus and the immune system: a concise review. Rev Med Virol. 2005;15(2):135-66.
9. Thiel S, Frederiksen PD, Jensens U. Clinical manifestations of mannan-binding lectin deficiency. Mol Immunol. 2006;43(3-4):286-96.
10. Brown KS, Ryder SD, Irving WL, Sim RB, Hickling TP. Mannan binding lectin and viral hepatitis. Immunol Lett. 2007;108(1):33-44.
11. Garred P, Larsen F, Madsen HO, Koch C. Mannan-binding lectin deficiency revisited. Mol Immunol. 2003;40(4-7):71-44.
12. Turner MW. The role of mannan-binding lectin in health and disease. Mol Immunol. 2003;40(7):423-9.
13. Matsuhashi M, Hijikata M, Ohta Y, Iwata K, Matsumoto M, Nakao K, et al. Hepatitis C virus infection and mutations of mannose-binding lectin gene MBL. J Immuol. 1998;161(3):1741-51.
14. Matsuhashi M, Hijikata M, Ohta Y, Mishiro S. Association of mannan-binding lectin gene haplotype IXP1 and IYP with interferon-resistant hepatitis C virus infection in Japanese patients. J Hepatol. 1998;28(5):970-7.
15. Sasaki K, Itsubumi A, Nakaya M, Ohtani K, Suzuki Y, Watanabe Y, et al. Mannose-binding lectin polymorphisms in patients with hepatitis C virus infection. Scand J Gastroenterol. 2000;35(9):960-5.
16. Segat I, Silva Vasconcelos LR, Montenegro de Melo F, Santos Silva B, Arreaes LC, Moura P, et al. Association of polymorphisms in the first exon of mannan binding lectin gene (MBL2) in Brazilian patients with HCV infection. Clin Immunol. 2007;124(2):33-7.
17. Somi MH, Farhang S, Asgharzadeh M, Estakhry R, Pouri AA. Mannose binding lectin gene haplotype in Iranian patients with hepatitis C infection. Hepat Mon. 2010;7(2):11-6.
18. Jack DL, Turner MW. Anti-microbial activities of mannan-binding lectin. Biochem Soc Trans. 2003;31(Pt 1):753-7.
19. Kilpatrick DC, Delahooke TE, Koch C, Turner ML, Hayes PC. Mannan-binding lectin and hepatitis C infection. Clin Exp Immunol. 2003;134(3):52-5.
20. Kirkpatrick BD, Huston CD, Wagner D, Noel F, Rouzier P, Pape JW, et al. Serum mannan-binding lectin deficiency is associated with cryptosporidiosis in young Haitian children. Clin Infect Dis. 2005;40(5):288-94.
21. Ishak K, Baptista A, Bianchi L, Callea F, Groote JD, Gadfut F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696-9.
22. Ribero M, Tremolada F, Chiaromonte S. HCV detection in non-A, non-B patients groups. In: Polders I, Stuyck M, editors. New challenges in the field of hepatitis C. Euro publisher (Belgium); 1993. p. 710.
23. Abdel-Wahab MF, Zakaria S, Kamel M, Abdel-Khaliq MK, Mabrouk MA, Salama H, et al. High seroprevalence of hepatitis C infection among risk groups in Egypt. Am J Trop Med Hyg. 1994;50(3):563-7.
24. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of paternal antisichertosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355(9207):887-91.
25. Heydrmann M, Shields P, McFarland G, Adams D. Cytokines and chemokines in the immune response to hepatitis C infection.
Serum Mannan-Binding Lectin and Chronic Hepatitis C

26. Thiel S, Holmsovk U, Hvid L, Laursen SB, Jensenius JC. The concentration of the C-type lectin, mannan-binding protein, in human plasma increases during an acute phase response. *Clin Exp Immunol*. 1992;90(1):31-5.

27. Yuen MF, Lau CS, Lau YL, Wong WM, Cheng CC, Lai CL. Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection. *Hepatology*. 1999;29(4):1248-51.

28. Brown KS, Keogh MJ, Tagiuri N, Grainge MJ, Presanis JS, Ryder SD, et al. Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex. *Clin Exp Immunol*. 2007;147(1):90-8.

29. Bruce MG, Bruden D, McMahon BJ, Christensen C, Homan C, Sullivan D, et al. Clinical significance of elevated alpha-fetoprotein in Alaskan Native patients with chronic hepatitis C. *J Viral Hepat*. 2008;15(3):379-87.

30. Hohler T, Wunschel M, Gerken G, Schneider PM, Meyer zum Buschenfeld KH, Rittner C. No association between mannose-binding lectin alleles and susceptibility to chronic hepatitis B virus infection in German patients. *Exp Clin Immunogenet*. 1998;15(3):210-3.